WILMINGTON, Mass. and OKLAHOMA CITY, Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreement with Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in pharma services, to offer Wheeler Bio's Portable CMC® (Chemistry, Manufacturing and Controls) platform to Charles River Laboratory clients. The collaboration is designed to enable a swift transition from pre-clinical stages directl ...

Charles River Laboratories International, Inc. (CRL) recently announced a strategic partnership with Wheeler Bio, an antibody CDMO (contract development and manufacturing organization) focused on the pre-clinical and early clinical supply of recombinant proteins, providing clients with access to Wheeler’s Portable CMC (Chemistry, Manufacturing and Controls) platform. The new alliance provides early-stage biotechnology companies with a unique solution to rapidly transition from pre-clinical activities to fir ...

Charles River Laboratories (CRL) continues to gain from the CRADL initiative. However, the competitive landscape is a concern. The stock carries a Zacks Rank #3 (Hold) currently.Research Models and Services (RMS) business services are in high demand among Charles River’s clients in the field of basic research and screening of non-clinical drug candidates. The RMS segment continues to benefit from broad-based growth in all geographic regions for small research models. Through most of 2023, the company witnes ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of ...

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2023 Results Conference Call February 14, 2024 8:30 AM ET Company Participants Todd Spencer - Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Derek De Bruin - Bank of America Patrick Donnelly - Citigroup Elizabeth Anderson - Evercore ISI David Windley - Jefferies LLC Justin Bowers - Deutsche Bank Jacob Johnson ...

Charles River Laboratories International, Inc. (CRL) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.46, which reflected a 17.4% decrease year over year. However, the metric surpassed the Zacks Consensus Estimate by 2.9%.On a GAAP basis, earnings declined 0.8% year over year to $3.62 per share. The year-over-year decrease in GAAP earnings was primarily due to lower revenues and operating income.For the full year, adjusted EPS was $10.67 per share, down 4% from the year-ago period’s leve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Its Cha ...

Charles River Laboratories International, Inc. (CRL) is likely to grow in the coming quarters, backed by the strong prospects of the RMS (Research Models and Services) segment. Presently, the company is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide. Stable solvency is an added upside.However, headwinds related to foreign exchange fluctuations and competitive pressure remain concerning for CRL’s operations.In the past year, this Za ...

Wall Street analysts expect Charles River Laboratories (CRL) to post quarterly earnings of $2.39 per share in its upcoming report, which indicates a year-over-year decline of 19.8%. Revenues are expected to be $985.69 million, down 10.4% from the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a co ...

Charles River Laboratories International, Inc. (CRL) is scheduled to report fourth-quarter and full-year 2023 results on Feb 14, before market open.In the last reported quarter, the company’s adjusted earnings per share of $2.72 surpassed the Zacks Consensus Estimate by 15.7%. Earnings surpassed estimates in each of the trailing four quarters, the average beat being 8.43%.Let’s take a look at how things have shaped up prior to this announcement.Factors at PlayThe Research Models and Services (RMS) segment i ...